Information de reference pour ce titreAccession Number: | 01445416-201605000-00002.
|
Author: | Beeson, James G.; Drew, Damien R.; Boyle, Michelle J.; Feng, Gaoqian; Fowkes, Freya J.I.; Richards, Jack S.
|
Institution: | (1)Burnet Institute for Medical Research and Public Health, 85 Commercial Road, Melbourne, Victoria, Australia (2)Department of Microbiology, Monash University, Clayton, Victoria, Australia (3)Department of Medicine, University of Melbourne, Parkville, Victoria, Australia (4)Department of Epidemiology and Preventive Medicine, Monash University, Clayton, Victoria, Australia (5)School of Population Health, University of Melbourne, Parkville, Victoria, Australia
|
Title: | |
Source: | Fems Microbiology Reviews. 40(3):343-372, May 2016.
|
Abstract: | Malaria accounts for an enormous burden of disease globally, with Plasmodium falciparum accounting for the majority of malaria, and P. vivax being a second important cause, especially in Asia, the Americas and the Pacific. During infection with Plasmodium spp., the merozoite form of the parasite invades red blood cells and replicates inside them. It is during the blood-stage of infection that malaria disease occurs and, therefore, understanding merozoite invasion, host immune responses to merozoite surface antigens, and targeting merozoite surface proteins and invasion ligands by novel vaccines and therapeutics have been important areas of research. Merozoite invasion involves multiple interactions and events, and substantial processing of merozoite surface proteins occurs before, during and after invasion. The merozoite surface is highly complex, presenting a multitude of antigens to the immune system. This complexity has proved challenging to our efforts to understand merozoite invasion and malaria immunity, and to developing merozoite antigens as malaria vaccines. In recent years, there has been major progress in this field, and several merozoite surface proteins show strong potential as malaria vaccines. Our current knowledge on this topic is reviewed, highlighting recent advances and research priorities.
Copyright (C) Oxford University Press 2015
|
Author Keywords: | Plasmodium falciparum; Plasmodium vivax; merozoites; invasion; immunity; vaccines; antibodies.
|
References: | Adams JH, Sim BK, Dolan SA, et al. A family of erythrocyte binding proteins of malaria parasites P Natl Acad Sci USA 1992 89 7085-9
Adams JH, Blair PL, Kaneko O, et al. An expanding ebl family of Plasmodium falciparum Trends Parasitol 2001 17 297-9
Adda CG, Murphy VJ, Sunde M, et al. Plasmodium falciparum merozoite surface protein 2 is unstructured and forms amyloid-like fibrils Mol Biochem Parasit 2009 166 159-71
Aikawa M, Miller LH, Johnson J, et al. Erythrocyte entry by malarial parasites. a moving junction between erythrocyte and parasite J Cell Biol 1978 77 72-82
Alonso PL, Smith T, Schellenberg JR, et al. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania [see comments] Lancet 1994 344 1175-81
Arevalo-Pinzon G, Bermudez M, Curtidor H, et al. The Plasmodium vivax rhoptry neck protein 5 is expressed in the apical pole of Plasmodium vivax VCG-1 strain schizonts and binds to human reticulocytes Malaria J 2015 14 106
Arevalo-Pinzon G, Curtidor H, Patino LC, et al. PvRON2, a new Plasmodium vivax rhoptry neck antigen Malaria J 2011 10 60
Arevalo-Pinzon G, Curtidor H, Abril J, et al. Annotation and characterization of the Plasmodium vivax rhoptry neck protein 4 (PvRON4) Malar J 2013 12 356
Arumugam TU, Takeo S, Yamasaki T, et al. Discovery of GAMA, a Plasmodium falciparum merozoite micronemal protein, as a novel blood-stage vaccine candidate antigen Infect Immun 2011 79 4523-32
Audran R, Cachat M, Lurati F, et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen Infect Immun 2005 73 8017-26
Badiane AS, Bei AK, Ahouidi AD, et al. Inhibitory humoral responses to the Plasmodium falciparum vaccine candidate EBA-175 are independent of the erythrocyte invasion pathway Clin Vaccine Immunol 2013 20 1238-45
Baker RP, Wijetilaka R, Urban S Two Plasmodium rhomboid proteases preferentially cleave different adhesins implicated in all invasive stages of malaria PLoS Pathog 2006 2 e113
Baldwin MR, Li X, Hanada T, et al. Merozoite surface protein 1 recognition of host glycophorin A mediates malaria parasite invasion of red blood cells Blood 2015 125 2704-11
Bannister LH, Butcher GA, Dennis ED, et al. Structure and invasive behaviour of Plasmodium knowlesi merozoites in vitro Parasitology 1975 71 483-91
Bargieri DY, Andenmatten N, Lagal V, et al. Apical membrane antigen 1 mediates apicomplexan parasite attachment but is dispensable for host cell invasion Nat Commun 2013 4 2552
Barron C Transcription of the gene for the merozoite surface antigen MSA2 of the human malaria parasite Plasmodium falciparum during the asexual cycle FEBS Lett 1992 300 77-81
Barry AE, Schultz L, Buckee CO, et al. Contrasting population structures of the genes encoding ten leading vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparum PLoS One 2009 4 e8497
Bartholdson SJ, Bustamante LY, Crosnier C, et al. Semaphorin-7A is an erythrocyte receptor for P. falciparum merozoite-specific TRAP homolog, MTRAP PLoS Pathog 2012 8 e1003031
Batchelor JD, Malpede BM, Omattage NS, et al. Red blood cell invasion by Plasmodium vivax: structural basis for DBP engagement of DARC PLoS Pathog 2014 10 e1003869
Batchelor JD, Zahm JA, Tolia NH Dimerization of Plasmodium vivax DBP is induced upon receptor binding and drives recognition of DARC Nat Struct Mol Biol 2011 18 908-14
Baum J, Richard D, Healer J, et al. A conserved molecular motor drives cell invasion and gliding motility across malaria life cycle stages and other apicomplexan parasites J Biol Chem 2006 281 5197-208
Baum J, Chen L, Healer J, et al. Reticulocyte-binding protein homologue 5 - an essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum Int J Parasitol 2009 39 371-80
Beeson J, Fowkes FJ, Reiling L, et al. Correlates of protection for Plasmodium falciparum malaria vaccine development: current knowledge and future research Corradin G, Engers H Malaria Vaccine Development: Over 40 Years of Trials and Tribulations London Future Medicine 2014 81-104
Beeson JG, Osier FH, Engwerda CR Recent insights into humoral and cellular immune responses against malaria Trends Parasitol 2008 24 578-84
Belard S, Issifou S, Hounkpatin AB, et al. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children PLoS One 2011 6 e22525
Besteiro S, Michelin A, Poncet J, et al. Export of a Toxoplasma gondii rhoptry neck protein complex at the host cell membrane to form the moving junction during invasion PLoS Pathog 2009 5 e1000309
Biswas S, Choudhary P, Elias SC, et al. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure PLoS One 2014 9 e107903
Black CG, Barnwell JW, Huber CS, et al. The Plasmodium vivax homologues of merozoite surface proteins 4 and 5 from Plasmodium falciparum are expressed at different locations in the merozoite Mol Biochem Parasit 2002 120 215-24
Black CG, Wang L, Hibbs AR, et al. Identification of the Plasmodium chabaudi homologue of merozoite surface proteins 4 and 5 of Plasmodium falciparum Infect Immun 1999 67 2075-81
Black CG, Wang L, Wu T, et al. Apical location of a novel EGF-like domain-containing protein of Plasmodium falciparum Mol Biochem Parasit 2003 127 59-68
Blackman MJ Purification of Plasmodium falciparum merozoites for analysis of the processing of merozoite surface protein-1 Methods Cell Biol 1994 45 213-20
Blackman MJ, Chappel JA, Shai S, et al. A conserved parasite serine protease processes the Plasmodium falciparum merozoite surface protein-1 Mol Biochem Parasit 1993 62 103-14
Blackman MJ, Dennis ED, Hirst EM, et al. Plasmodium knowlesi: secondary processing of the malaria merozoite surface protein-1 Exp Parasitol 1996 83 229-39
Blackman MJ, Heidrich HG, Donachie S, et al. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies J Exp Med 1990 172 379-82
Blackman MJ, Holder AA Secondary processing of the Plasmodium falciparum merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1 Mol Biochem Parasit 1992 50 307-15
Blackman MJ, Scott-Finnigan TJ, Shai S, et al. Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein J Exp Med 1994 180 389-93
Borre MB, Dziegiel M, Hogh B, et al. Primary structure and localization of a conserved immunogenic Plasmodium falciparum glutamate rich protein (GLURP) expressed in both the preerythrocytic and erythrocytic stages of the vertebrate life cycle Mol Biochem Parasit 1991 49 119-31
Bouharoun-Tayoun H, Oeuvray C, Lunel F, et al. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages J Exp Med 1995 182 409-18
Bowyer PW, Stewart LB, Aspeling-Jones H, et al. Variation in Plasmodium falciparum Erythrocyte Invasion Phenotypes and Merozoite Ligand Gene Expression across Different Populations in Areas of Malaria Endemicity Infect Immun 2015 83 2575-82
Boyle MJ, Langer C, Chan JA, et al. Sequential processing of merozoite surface proteins during and after erythrocyte invasion by Plasmodium falciparum Infect Immun 2014 82 924-36
Boyle MJ, Reiling L, Feng G, et al. Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria Immunity 2015 42 580-90
Boyle MJ, Richards JS, Gilson PR, et al. Interactions with heparin-like molecules during erythrocyte invasion by Plasmodium falciparum merozoites Blood 2010a 115 4559-68
Boyle MJ, Wilson DW, Beeson JG New approaches to studying Plasmodium falciparum merozoite invasion and insights into invasion biology Int J Parasitol 2013 43 1-10
Boyle MJ, Wilson DW, Richards JS, et al. Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development P Natl Acad Sci USA 2010b 107 14378-83
Buscaglia CA, Coppens I, Hol WG, et al. Sites of interaction between aldolase and thrombospondin-related anonymous protein in plasmodium Mol Biol Cell 2003 14 4947-57
Carlton JM, Adams JH, Silva JC, et al. Comparative genomics of the neglected human malaria parasite Plasmodium vivax Nature 2008 455 757-63
Carruthers VB, Blackman MJ A new release on life: emerging concepts in proteolysis and parasite invasion Mol Microbiol 2005 55 1617-30
Chan JA, Howell KB, Reiling L, et al. Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity J Clin Invest 2012 122 3227-38
Chandramohanadas R, Basappa , Russell B, et al. Small molecule targeting malaria merozoite surface protein-1 (MSP-1) prevents host invasion of divergent plasmodial species J Infect Dis 2014 210 1616-26
Chen L, Lopaticki S, Riglar DT, et al. An EGF-like protein forms a complex with PfRh5 and is required for invasion of human erythrocytes by Plasmodium falciparum PLoS Pathog 2011 7 e1002199
Cheng Y, Li J, Ito D, et al. Antigenicity and immunogenicity of PvRALP1, a novel Plasmodium vivax rhoptry neck protein Malaria J 2015 14 186
Cheng Y, Wang Y, Ito D, et al. The Plasmodium vivax merozoite surface protein 1 paralog is a novel erythrocyte-binding ligand of P. vivax Infect Immun 2013 81 1585-95
Child MA, Epp C, Bujard H, et al. Regulated maturation of malaria merozoite surface protein-1 is essential for parasite growth Mol Microbiol 2010 78 187-202
Child MA, Harris PK, Collins CR, et al. Molecular determinants for subcellular trafficking of the malarial sheddase PfSUB2 Traffic 2013 14 1053-64
Chitnis CE, Mukherjee P, Mehta S, et al. Phase I clinical trial of a recombinant blood stage vaccine candidate for Plasmodium Falciparum malaria based on MSP1 and EBA175 PLoS One 2015 10 e0117820
Chiu CY, Hodder AN, Lin CS, et al. Antibodies to the Plasmodium falciparum proteins MSPDBL1 and MSPDBL2 opsonize merozoites, inhibit parasite growth, and predict protection from clinical malaria J Infect Dis 2015 212 406-15
Clark JT, Donachie S, Anand R, et al. 46-53 kilodalton glycoprotein from the surface of Plasmodium falciparum merozoites Mol Biochem Parasit 1989 32 15-24
Cole-Tobian JL, Michon P, Biasor M, et al. Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous Plasmodium vivax strains in Papua New Guinean children Infect Immun 2009 77 4009-17
Conway DJ Paths to a malaria vaccine illuminated by parasite genomics Trends Genet 2015 31 97-107
Crompton PD, Kayala MA, Traore B, et al. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray P Natl Acad Sci USA 2010 107 6958-63
Crosnier C, Bustamante LY, Bartholdson SJ, et al. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum Nature 2011 480 534-7
Cutts J, Powell R, Agius P, et al. Immunological markers of P. vivax exposure and immunity: a systematic review and meta-analysis BMC Medicine 2014 12 150
D'Alessandro U, Leach A, Drakeley CJ, et al. Efficacy trial of malaria vaccine SPf66 in Gambian infants Lancet 1995 346 462-7
Das S, Hertrich N, Perrin AJ, et al. Processing of Plasmodium falciparum merozoite surface protein msp1 activates a spectrin-binding function enabling parasite egress from RBCs Cell Host Microbe 2015 18 433-44
Debrabant A, Delplace P Leupeptin alters the proteolytic processing of P126, the major parasitophorous vacuole antigen of Plasmodium falciparum Mol Biochem Parasit 1989 33 151-8
Delplace P, Fortier B, Tronchin G, et al. Localization, biosynthesis, processing and isolation of a major 126 kDa antigen of the parasitophorous vacuole of Plasmodium falciparum Mol Biochem Parasit 1987 23 193-201
Dent AE, Nakajima R, Liang L, et al. Plasmodium falciparum protein microarray antibody profiles correlate with protection from symptomatic malaria in Kenya J Infect Dis 2015 212 1429-38
Dicko A, Diemert DJ, Sagara I, et al. Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians PLoS One 2007 2 e1045
Dicko A, Sagara I, Ellis RD, et al. Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children PLoS One 2008 3 e1563
Dluzewski AR, Ling IT, Hopkins JM, et al. Formation of the food vacuole in Plasmodium falciparum: a potential role for the 19 kDa fragment of merozoite surface protein 1 (MSP1(19)) PLoS One 2008 3 e3085
Dobano C, Quelhas D, Quinto L, et al. Age-dependent IgG subclass responses to Plasmodium falciparum EBA-175 are differentially associated with incidence of malaria in Mozambican children Clin Vaccine Immunol 2012 19 157-66
Dolan SA, Miller LH, Wellems TE Evidence for a switching mechanism in the invasion of erythrocytes by Plasmodium falciparum J Clin Invest 1990 86 618-24
Doolan DL, Mu Y, Unal B, et al. Profiling humoral immune responses to P. falciparum infection with protein microarrays Proteomics 2008 8 4680-94
Douglas AD, Baldeviano GC, Lucas CM, et al. A PfRH5-based vaccine is efficacious against Heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys Cell Host Microbe 2015 17 130-9
Drakeley C, Cook J Chapter 5. Potential contribution of sero-epidemiological analysis for monitoring malaria control and elimination: historical and current perspectives Adv Parasitol 2009 69 299-352
Drew DR, Beeson JG PfRH5 as a candidate vaccine for Plasmodium falciparum malaria Trends Parasitol 2015 31 87-8
Drew DR, Hodder AN, Wilson DW, et al. Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria PLoS One 2012 7 e51023
Dreyer AM, Matile H, Papastogiannidis P, et al. Passive immunoprotection of Plasmodium falciparum-infected mice designates the CyRPA as candidate malaria vaccine antigen J Immunol 2012 188 6225-37
Druilhe P, Spertini F, Soesoe D, et al. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum PLoS Med 2005 2 e344
Duncan CJ, Sheehy SH, Ewer KJ, et al. Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909 PLoS One 2011 6 e22271
Dups JN, Pepper M, Cockburn IA Antibody and B cell responses to Plasmodium sporozoites Front Microbiol 2014 5 625
Duraisingh MT, Triglia T, Ralph SA, et al. Phenotypic variation of Plasmodium falciparum merozoite proteins directs receptor targeting for invasion of human erythrocytes EMBO J 2003 22 1047-57
Dutta S, Dlugosz LS, Drew DR, et al. Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1 PLoS Pathog 2013 9 e1003840
Dutta S, Haynes JD, Moch JK, et al. Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites P Natl Acad Sci USA 2003 100 12295-300
Dvorin JD, Bei AK, Coleman BI, et al. Functional diversification between two related Plasmodium falciparum merozoite invasion ligands is determined by changes in the cytoplasmic domain Mol Microbiol 2010 75 990-1006
Egan AF, Burghaus P, Druilhe P, et al. Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro Parasite Immunol 1999 21 133-9
Egan ES, Jiang RH, Moechtar MA, et al. Malaria. A forward genetic screen identifies erythrocyte CD55 as essential for Plasmodium falciparum invasion Science 2015 348 711-4
El Sahly HM, Patel SM, Atmar RL, et al. Safety and immunogenicity of a recombinant nonglycosylated EBA175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic Clin Vaccine Immunol 2010 17 1552-9
Elliott SR, Fowkes FJ, Richards JS, et al. Research priorities for the development and implementation of serological tools for malaria surveillance F1000 Prime Rep 2014 6 100
Ellis RD, Wu Y, Martin LB, et al. Phase 1 study in malaria naive adults of BSAM2/Alhydrogel(R)+CPG 7909, a blood stage vaccine against P. falciparum malaria PLoS One 2012 7 e46094
Esen M, Kremsner PG, Schleucher R, et al. Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate Vaccine 2009 27 6862-8
Fenton B, Clark JT, Khan CM, et al. Structural and antigenic polymorphism of the 35- to 48-kilodalton merozoite surface antigen (MSA-2) of the malaria parasite Plasmodium falciparum Mol Cell Biol 1991 11 963-71
Fernandez-Becerra C, Sanz S, Brucet M, et al. Naturally-acquired humoral immune responses against the N- and C-termini of the Plasmodium vivax MSP1 protein in endemic regions of Brazil and Papua New Guinea using a multiplex assay Malaria J 2010 9 29
Fleck SL, Birdsall B, Babon J, et al. Suramin and suramin analogues inhibit merozoite surface protein-1 secondary processing and erythrocyte invasion by the malaria parasite Plasmodium falciparum J Biol Chem 2003 278 47670-7
Fowkes FJ, Richards JS, Simpson JA, et al. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis PLoS Med 2010 7 e1000218
Fowkes FJ, McGready R, Cross NJ, et al. New insights into acquisition, boosting, and longevity of immunity to malaria in pregnant women J Infect Dis 2012 206 1612-21
Gao X, Gunalan K, Yap SS, et al. Triggers of key calcium signals during erythrocyte invasion by Plasmodium falciparum Nat Commun 2013 4 2862
Gao X, Yeo KP, Aw SS, et al. Antibodies targeting the PfRH1 binding domain inhibit invasion of Plasmodium falciparum merozoites PLoS Pathog 2008 4 e1000104
Garcia Y, Puentes A, Curtidor H, et al. Identifying merozoite surface protein 4 and merozoite surface protein 7 Plasmodium falciparum protein family members specifically binding to human erythrocytes suggests a new malarial parasite-redundant survival mechanism J Med Chem 2007 50 5665-75
Gaur D, Furuya T, Mu J, et al. Upregulation of expression of the reticulocyte homology gene 4 in the Plasmodium falciparum clone Dd2 is associated with a switch in the erythrocyte invasion pathway Mol Biochem Parasit 2006 145 205-15
Genton B, Al-Yaman F, Anders R, et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea Vaccine 2000 18 2504-11
Genton B, Al-Yaman F, Betuela I, et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children Vaccine 2003 22 30-41
Genton B, Betuela I, Felger I, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in PNG J Infect Dis 2002 185 820-7
Genton B, Pluschke G, Degen L, et al. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers PLoS One 2007 2 e1018
Gerloff DL, Creasey A, Maslau S, et al. Structural models for the protein family characterized by gamete surface protein Pfs230 of Plasmodium falciparum P Natl Acad Sci USA 2005 102 13598-603
Gilberger TW, Thompson JK, Triglia T, et al. A novel erythrocyte binding antigen-175 paralogue from Plasmodium falciparum defines a new trypsin-resistant receptor on human erythrocytes J Biol Chem 2003 278 14480-6
Gilson PR, Crabb BS Morphology and kinetics of the three distinct phases of red blood cell invasion by Plasmodium falciparum merozoites Int J Parasitol 2009 39 91-6
Gilson PR, Nebl T, Vukcevic D, et al. Identification and stoichiometry of glycosylphosphatidylinositol-anchored membrane proteins of the human malaria parasite Plasmodium falciparum Mol Cell Proteomics 2006 5 1286-99
Giovannini D, Spath S, Lacroix C, et al. Independent roles of apical membrane antigen 1 and rhoptry neck proteins during host cell invasion by apicomplexa Cell Host Microbe 2011 10 591-602
Goel VK, Li X, Chen H, et al. Band 3 is a host receptor binding merozoite surface protein 1 during the Plasmodium falciparum invasion of erythrocytes P Natl Acad Sci USA 2003 100 5164-9
Graves P, Gelband H Vaccines for preventing malaria (SPf66) Cochrane Db Syst Rev 2006 CD005966
Gray JC, Corran PH, Mangia E, et al. Profiling the antibody immune response against blood stage malaria vaccine candidates Clin Chem 2007 53 1244-53
Green JL, Hinds L, Grainger M, et al. Plasmodium thrombospondin related apical merozoite protein (PTRAMP) is shed from the surface of merozoites by PfSUB2 upon invasion of erythrocytes Mol Biochem Parasit 2006 150 114-7
Grimberg BT, Udomsangpetch R, Xainli J, et al. Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein PLoS Med 2007 4 e337
Haase S, Cabrera A, Langer C, et al. Characterization of a conserved rhoptry-associated leucine zipper-like protein in the malaria parasite Plasmodium falciparum Infect Immun 2008 76 879-87
Harris PK, Yeoh S, Dluzewski AR, et al. Molecular identification of a malaria merozoite surface sheddase PLoS Pathog 2005 1 241-51
He XL, Grigg ME, Boothroyd JC, et al. Structure of the immunodominant surface antigen from the Toxoplasma gondii SRS superfamily Nat Struct Biol 2002 9 606-11
Healer J, Thompson JK, Riglar DT, et al. Vaccination with conserved regions of erythrocyte-binding antigens induces neutralizing antibodies against multiple strains of Plasmodium falciparum PLoS One 2013 8 e72504
Hermsen CC, Verhage DF, Telgt DS, et al. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial Vaccine 2007 25 2930-40
Hill DL, Eriksson EM, Li Wai Suen CS, et al. Opsonising antibodies to P. falciparum merozoites associated with immunity to clinical malaria PLoS One 2013 8 e74627
Hinds L, Green JL, Knuepfer E, et al. Novel putative glycosylphosphatidylinositol-anchored micronemal antigen of Plasmodium falciparum that binds to erythrocytes Eukaryot Cell 2009 8 1869-79
Hodder AN, Crewther PE, Anders RF Specificity of the protective antibody response to apical membrane antigen 1 Infect Immun 2001 69 3286-94
Hodder AN, Crewther PE, Matthew ML, et al. The disulfide bond structure of Plasmodium apical membrane antigen-1 J Biol Chem 1996 271 29446-52
Hodder AN, Drew DR, Epa VC, et al. Enzymic, phylogenetic, and structural characterization of the unusual papain-like protease domain of Plasmodium falciparum SERA5 J Biol Chem 2003 278 48169-77
Hogh B, Thompson R, Zakiuddin IS, et al. Glutamate rich Plasmodium falciparum antigen (GLURP) Parassitologia 1993 35 Suppl 47-50
Holder AA The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria Parasitology 2009 136 1445-56
Horii T, Shirai H, Jie L, et al. Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36 Parasitol Int 2010 59 380-6
Howell SA, Hackett F, Jongco AM, et al. Distinct mechanisms govern proteolytic shedding of a key invasion protein in apicomplexan pathogens Mol Microbiol 2005 57 1342-56
Hu J, Chen Z, Gu J, et al. Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults PLoS One 2008 3 e1952
Irani V, Ramsland PA, Guy AJ, et al. Acquisition of functional antibodies that block the binding of erythrocyte binding antigen 175 and protection from Plasmodium falciparum malaria in children Clin Infect Dis 2015 61 1244-52
Ishino T, Chinzei Y, Yuda M Two proteins with 6-cys motifs are required for malarial parasites to commit to infection of the hepatocyte Mol Microbiol 2005 58 1264-75
Ito D, Hasegawa T, Miura K, et al. RALP1 is a rhoptry neck erythrocyte-binding protein of Plasmodium falciparum merozoites and a potential blood-stage vaccine candidate antigen Infect Immun 2013 81 4290-8
Jacquet A, Coulon L, De Neve J, et al. The surface antigen SAG3 mediates the attachment of Toxoplasma gondii to cell-surface proteoglycans Mol Biochem Parasit 2001 116 35-44
Jepsen MP, Jogdand PS, Singh SK, et al. The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas J Infect Dis 2013 208 479-88
Jones TR, Narum DL, Gozalo AS, et al. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen J Infect Dis 2001 183 303-12
Joos C, Marrama L, Polson HE, et al. Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies PLoS One 2010 5 e9871
Kadekoppala M, Holder AA Merozoite surface proteins of the malaria parasite: the MSP1 complex and the MSP7 family Int J Parasitol 2010 40 1155-61
Kadekoppala M, O'Donnell RA, Grainger M, et al. Deletion of the Plasmodium falciparum merozoite surface protein 7 gene impairs parasite invasion of erythrocytes Eukaryot Cell 2008 7 2123-32
Kano FS, Sanchez BA, Sousa TN, et al. Plasmodium vivax Duffy binding protein: baseline antibody responses and parasite polymorphisms in a well-consolidated settlement of the Amazon Region Trop Med Int Health 2012 17 989-1000
Kariuki MM, Li X, Yamodo I, et al. Two Plasmodium falciparum merozoite proteins binding to erythrocyte band 3 form a direct complex Biochem Bioph Res Co 2005 338 1690-5
Kauth CW, Epp C, Bujard H, et al. The merozoite surface protein 1 complex of human malaria parasite Plasmodium falciparum: interactions and arrangements of subunits J Biol Chem 2003 278 22257-64
Kauth CW, Woehlbier U, Kern M, et al. Interactions between merozoite surface proteins 1, 6, and 7 of the malaria parasite Plasmodium falciparum J Biol Chem 2006 281 31517-27
Keitel WA, Kester KE, Atmar RL, et al. Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid Vaccine 1999 18 531-9
Khusmith S, Druilhe P Specific arming of monocytes by cytophilic IgG promotes Plasmodium falciparum merozoite ingestion T Roy Soc Trop Med H 1982 76 423-4
Khusmith S, Druilhe P, Gentilini M Enhanced Plasmodium falciparum merozoite phagocytosis by monocytes from immune individuals Infect Immun 1982 35 874-9
King CL, Michon P, Shakri AR, et al. Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection P Natl Acad Sci USA 2008 105 8363-8
Knapp B, Nau U, Hundt E, et al. A new blood stage antigen of Plasmodium falciparum highly homologous to the serine-stretch protein SERP Mol Biochem Parasit 1991 44 1-13
Koussis K, Withers-Martinez C, Yeoh S, et al. A multifunctional serine protease primes the malaria parasite for red blood cell invasion EMBO J 2009 28 725-35
Ladda R, Aikawa M, Sprinz H Penetration of erythrocytes by merozoites of mammalian and avian malarial parasites J Parasitol 1969 55 633-44
Lamarque M, Besteiro S, Papoin J, et al. The RON2-AMA1 interaction is a critical step in moving junction-dependent invasion by apicomplexan parasites PLoS Pathog 2011 7 e1001276
Lamarque MH, Roques M, Kong-Hap M, et al. Plasticity and redundancy among AMA-RON pairs ensure host cell entry of Toxoplasma parasites Nat Commun 2014 5 4098
Langreth SG, Nguyen-Dinh P, Trager W Plasmodium falciparum: merozoite invasion in vitro in the presence of chloroquine Exp Parasitol 1978 46 235-8
Lanzillotti R, Coetzer TL The 10 kDa domain of human erythrocyte protein 4.1 binds the Plasmodium falciparum EBA-181 protein Malaria J 2006 5 100
Lawrence G, Cheng QQ, Reed C, et al. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers Vaccine 2000 18 1925-31
Leykauf K, Treeck M, Gilson PR, et al. Protein kinase a dependent phosphorylation of apical membrane antigen 1 plays an important role in erythrocyte invasion by the malaria parasite PLoS Pathog 2010 6 e1000941
Li J, Han ET Dissection of the Plasmodium vivax reticulocyte binding-like proteins (PvRBPs) Biochem Bioph Res Co 2012 426 1-6
Lima-Junior JC, Jiang J, Rodrigues-da-Silva RN, et al. B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax merozoite surface protein-3alpha (PvMSP-3alpha) in malaria exposed individuals from Brazilian Amazon Vaccine 2011 29 1801-11
Lima-Junior JC, Rodrigues-da-Silva RN, Banic DM, et al. Influence of HLA-DRB1 and HLA-DQB1 alleles on IgG antibody response to the P. vivax MSP-1, MSP-3alpha and MSP-9 in individuals from Brazilian endemic area PLoS One 2012 7 e36419
Lima-Junior JC, Tran TM, Meyer EV, et al. Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individuals Vaccine 2008 26 6645-54
Lobo CA, Rodriguez M, Reid M, et al. Glycophorin C is the receptor for the Plasmodium falciparum erythrocyte binding ligand PfEBP-2 (baebl) Blood 2003 101 4628-31
Lopez R, Valbuena J, Rodriguez LE, et al. Plasmodium falciparum merozoite surface protein 6 (MSP-6) derived peptides bind erythrocytes and partially inhibit parasite invasion Peptides 2006 27 1685-92
Low A, Chandrashekaran IR, Adda CG, et al. Merozoite surface protein 2 of Plasmodium falciparum: expression, structure, dynamics, and fibril formation of the conserved N-terminal domain Biopolymers 2007 87 12-22
McCarra MB, Ayodo G, Sumba PO, et al. Antibodies to Plasmodium falciparum erythrocyte-binding antigen-175 are associated with protection from clinical malaria Pediatr Infect Dis J 2011 30 1037-42
McCarthy JS, Marjason J, Elliott S, et al. A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide(R) ISA 720 PLoS One 2011 6 e24413
McCoubrie JE, Miller SK, Sargeant T, et al. Evidence for a common role for the serine-type Plasmodium falciparum serine repeat antigen proteases: implications for vaccine and drug design Infect Immun 2007 75 5565-74
MacRaild CA, Pedersen MO, Anders RF, et al. Lipid interactions of the malaria antigen merozoite surface protein 2 Biochim Biophys Acta 2012 1818 2572-8
Maier AG, Baum J, Smith B, et al. Polymorphisms in erythrocyte binding antigens 140 and 181 affect function and binding but not receptor specificity in Plasmodium falciparum Infect Immun 2009 77 1689-99
Maier AG, Duraisingh MT, Reeder JC, et al. Plasmodium falciparum erythrocyte invasion through glycophorin C and selection for Gerbich negativity in human populations Nat Med 2003 9 87-92
Malkin E, Hu J, Li Z, et al. A Phase 1 trial of PfCP2.9: An AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria Vaccine 2008
Malkin EM, Diemert DJ, McArthur JH, et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria Infect Immun 2005 73 3677-85
Malleret B, Li A, Zhang R, et al. Plasmodium vivax: restricted tropism and rapid remodeling of CD71-positive reticulocytes Blood 2015 125 1314-24
Marshall VM, Tieqiao W, Coppel RL Close linkage of three merozoite surface protein genes on chromosome 2 of Plasmodium falciparum Mol Biochem Parasit 1998 94 13-25
Mayer DC, Cofie J, Jiang L, et al. Glycophorin B is the erythrocyte receptor of Plasmodium falciparum erythrocyte-binding ligand, EBL-1 P Natl Acad Sci USA 2009 106 5348-52
Mehrizi AA, Zakeri S, Salmanian AH, et al. Plasmodium falciparum: sequence analysis of the gene encoding the C-terminus region of the merozoite surface protein-1, a potential malaria vaccine antigen, in Iranian clinical isolates Exp Parasitol 2008 118 378-85
Mello K, Daly TM, Morrisey J, et al. A multigene family that interacts with the amino terminus of plasmodium MSP-1 identified using the yeast two-hybrid system Eukaryot Cell 2002 1 915-25
Menard R The journey of the malaria sporozoite through its hosts: two parasite proteins lead the way Microbes Infect 2000 2 633-42
Miller LH, Roberts T, Shahabuddin M, et al. Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1) Mol Biochem Parasit 1993 59 1-14
Miller SK, Good RT, Drew DR, et al. A subset of Plasmodium falciparum SERA genes are expressed and appear to play an important role in the erythrocytic cycle J Biol Chem 2002 277 47524-32
Mills KE, Pearce JA, Crabb BS, et al. Truncation of merozoite surface protein 3 disrupts its trafficking and that of acidic-basic repeat protein to the surface of Plasmodium falciparum merozoites Mol Microbiol 2002 43 1401-11
Miura K, Zhou H, Diouf A, et al. Immunological responses against Plasmodium falciparum Apical Membrane Antigen 1 vaccines vary depending on the population immunized Vaccine 2011 29 2255-61
Morahan BJ, Wang L, Coppel RL No TRAP, no invasion Trends Parasitol 2009 25 77-84
Mordmuller B, Szywon K, Greutelaers B, et al. Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene, Gabon Vaccine 2010 28 6698-703
Moreno-Perez DA, Degano R, Ibarrola N, et al. Determining the Plasmodium vivax VCG-1 strain blood stage proteome J Proteomics 2014 113C 268-80
Moss DK, Remarque EJ, Faber BW, et al. Plasmodium falciparum 19-kilodalton merozoite surface protein 1 (MSP1)-specific antibodies that interfere with parasite growth in vitro can inhibit MSP1 processing, merozoite invasion, and intracellular parasite development Infect Immun 2012 80 1280-7
Mullen GE, Ellis RD, Miura K, et al. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria PLoS One 2008 3 e2940
Narum DL, Thomas AW Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites Mol Biochem Parasit 1994 67 59-68
Nery S, Deans AM, Mosobo M, et al. Expression of Plasmodium falciparum genes involved in erythrocyte invasion varies among isolates cultured directly from patients Mol Biochem Parasit 2006 149 208-15
Nosten F, Luxemburger C, Kyle DE, et al. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group Lancet 1996 348 701-7
Ockenhouse CF, Angov E, Kester KE, et al. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine Vaccine 2006 24 3009-17
Ockenhouse CF, Sun PF, Lanar DE, et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum. malaria J Infect Dis 1998 177 1664-73
O'Donnell RA, de Koning-Ward TF, Burt RA, et al. Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria J Exp Med 2001 193 1403-12
O'Donnell RA, Hackett F, Howell SA, et al. Intramembrane proteolysis mediates shedding of a key adhesin during erythrocyte invasion by the malaria parasite J Cell Biol 2006 174 1023-33
Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, et al. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes Blood 1994 84 1594-602
Ogutu BR, Apollo OJ, McKinney D, et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya PLoS One 2009 4 e4708
Ohas EA, Adams JH, Waitumbi JN, et al. Measurement of antibody levels against region II of the erythrocyte-binding antigen 175 of Plasmodium falciparum in an area of malaria holoendemicity in western Kenya Infect Immun 2004 72 735-41
Okoyeh JN, Pillai CR, Chitnis CE Plasmodium falciparum field isolates commonly use erythrocyte invasion pathways that are independent of sialic acid residues of glycophorin A Infect Immun 1999 67 5784-91
Olivieri A, Collins CR, Hackett F, et al. Juxtamembrane shedding of Plasmodium falciparum AMA1 is sequence independent and essential, and helps evade invasion-inhibitory antibodies PLoS Pathog 2011 7 e1002448
Ondigo BN, Hodges JS, Ireland KF, et al. Estimation of recent and long-term malaria transmission in a population by antibody testing to multiple Plasmodium falciparum antigens J Infect Dis 2014 210 1123-32
Osier FH, Feng G, Boyle MJ, et al. Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria BMC Med 2014a 12 108
Osier FH, Fegan G, Polley SD, et al. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria Infect Immun 2008 76 2240-8
Osier FH, Mackinnon MJ, Crosnier C, et al. New antigens for a multicomponent blood-stage malaria vaccine Sci Transl Med 2014b 6 247ra102
Ouattara A, Mu J, Takala-Harrison S, et al. Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine Malaria J 2010 9 175
Pachebat JA, Kadekoppala M, Grainger M, et al. Extensive proteolytic processing of the malaria parasite merozoite surface protein 7 during biosynthesis and parasite release from erythrocytes Mol Biochem Parasit 2007 151 59-69
Pachebat JA, Ling IT, Grainger M, et al. The 22 kDa component of the protein complex on the surface of Plasmodium falciparum merozoites is derived from a larger precursor, merozoite surface protein 7 Mol Biochem Parasit 2001 117 83-9
Palacpac NM, Ntege E, Yeka A, et al. Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36 PLoS One 2013 8 e64073
Pasay MC, Cheng Q, Rzepczyk C, et al. Dimorphism of the C terminus of the Plasmodium vivax merozoite surface protein 1 Mol Biochem Parasit 1995 70 217-9
Pearce JA, Triglia T, Hodder AN, et al. Plasmodium falciparum merozoite surface protein 6 is a dimorphic antigen Infect Immun 2004 72 2321-8
Perraut R, Joos C, Sokhna C, et al. Association of antibody responses to the conserved Plasmodium falciparum merozoite surface protein 5 with protection against clinical malaria PLoS One 2014 9 e101737
Persson KE, Fowkes FJ, McCallum FJ, et al. Erythrocyte-binding antigens of Plasmodium falciparum are targets of human inhibitory antibodies and function to evade naturally acquired immunity J Immunol 2013 191 785-94
Persson KE, McCallum FJ, Reiling L, et al. Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies J Clin Invest 2008 118 342-51
Plassmeyer ML, Reiter K, Shimp RL, Jr, et al. Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate J Biol Chem 2009 284 26951-63
Polhemus ME, Magill AJ, Cummings JF, et al. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research Vaccine 2007 25 4203-12
Polson HE, Conway DJ, Fandeur T, et al. Gene polymorphism of Plasmodium falciparum merozoite surface proteins 4 and 5 Mol Biochem Parasit 2005 142 110-5
Price RN, Tjitra E, Guerra CA, et al. Vivax malaria: neglected and not benign Am J Trop Med Hyg 2007 77 79-87
Ramasamy R Studies on glycoproteins in the human malaria parasite Plasmodium falciparum. Identification of a myristilated 45kDa merozoite membrane glycoprotein Immunol Cell Biol 1987 65 Pt 5 419-24
Rayner JC, Galinski MR, Ingravallo P, et al. Two Plasmodium falciparum genes express merozoite proteins that are related to Plasmodium vivax and Plasmodium yoelii adhesive proteins involved in host cell selection and invasion P Natl Acad Sci USA 2000 97 9648-53
Rayner JC, Vargas-Serrato E, Huber CS, et al. Plasmodium falciparum homologue of Plasmodium vivax reticulocyte binding protein (PvRBP1) defines a trypsin-resistant erythrocyte invasion pathway J Exp Med 2001 194 1571-81
Reddy KS, Amlabu E, Pandey AK, et al. Multiprotein complex between the GPI-anchored CyRPA with PfRH5 and PfRipr is crucial for Plasmodium falciparum erythrocyte invasion P Natl Acad Sci USA 2015 112 1179-84
Reed MB, Caruana SR, Batchelor AH, et al. Targeted disruption of an erythrocyte binding antigen in Plasmodium falciparum is associated with a switch toward a sialic acid-independent pathway of invasion P Natl Acad Sci USA 2000 97 7509-14
Reiling L, Richards JS, Fowkes FJ, et al. Evidence that the erythrocyte invasion ligand PfRh2 is a target of protective immunity against Plasmodium falciparum malaria J Immunol 2010 185 6157-67
Reiling L, Richards JS, Fowkes FJ, et al. The Plasmodium falciparum erythrocyte invasion ligand Pfrh4 as a target of functional and protective human antibodies against malaria PLoS One 2012 7 e45253
Remarque EJ, Faber BW, Kocken CH, et al. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits Infect Immun 2008 76 2660-70
Rice BL, Acosta MM, Pacheco MA, et al. The origin and diversification of the merozoite surface protein 3 (msp3) multi-gene family in Plasmodium vivax and related parasites Mol Phylogenet Evol 2014 78 172-84
Richards JS, Arumugam TU, Reiling L, et al. Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development J Immunol 2013 191 795-809
Richards JS, Beeson JG The future for blood-stage vaccines against malaria Immunol Cell Biol 2009 87 377-90
Richards JS, Stanisic DI, Fowkes FJ, et al. Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia Clin Infect Dis 2010 51 e50-60
Riglar DT, Richard D, Wilson DW, et al. Super-resolution dissection of coordinated events during malaria parasite invasion of the human erythrocyte Cell Host Microbe 2011 9 9-20
Riglar DT, Whitehead L, Cowman AF, et al. Localization-based imaging of malarial antigens during red cell entry reaffirms role for AMA1 but not MTRAP in invasion J Cell Sci 2015 129 228-42
Roestenberg M, Remarque E, de Jonge E, et al. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02 PLoS One 2008 3 e3960
Roussilhon C, Oeuvray C, Muller-Graf C, et al. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3 PLoS Med 2007 4 e320
RTSS Clinical Trials Partnership Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial Lancet 2015 386 31-45
Ruecker A, Shea M, Hackett F, et al. Proteolytic activation of the essential parasitophorous vacuole cysteine protease SERA6 accompanies malaria parasite egress from its host erythrocyte J Biol Chem 2012 287 37949-63
Ryan JR, Stoute JA, Amon J, et al. Evidence for transmission of Plasmodium vivax among a duffy antigen negative population in Western Kenya Am J Trop Med Hyg 2006 75 575-81
Sagara I, Dicko A, Ellis RD, et al. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali Vaccine 2009a 27 3090-8
Sagara I, Ellis RD, Dicko A, et al. A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults Vaccine 2009b 27 7292-8
Sakamoto H, Takeo S, Maier AG, et al. Antibodies against a Plasmodium falciparum antigen PfMSPDBL1 inhibit merozoite invasion into human erythrocytes Vaccine 2012 30 1972-80
Sala KA, Nishiura H, Upton LM, et al. The Plasmodium berghei sexual stage antigen PSOP12 induces anti-malarial transmission blocking immunity both in vivo and in vitro Vaccine 2015 33 437-45
Sanders PR, Gilson PR, Cantin GT, et al. Distinct protein classes including novel merozoite surface antigens in Raft-like membranes of Plasmodium falciparum J Biol Chem 2005 280 40169-76
Sanders PR, Kats LM, Drew DR, et al. A set of glycosylphosphatidyl inositol-anchored membrane proteins of Plasmodium falciparum is refractory to genetic deletion Infect Immun 2006 74 4330-8
Santos J, Graindorge A, Soldati-Favre D New insights into parasite rhomboid proteases Mol Biochem Parasit 2012 182 27-36
Saul A Kinetic constraints on the development of a malaria vaccine Parasite Immunol 1987 9 1-9
Saul A, Lawrence G, Allworth A, et al. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant Vaccine 2005 23 3076-83
Saul A, Lawrence G, Smillie A, et al. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant Vaccine 1999 17 3145-59
Sheehy SH, Duncan CJ, Elias SC, et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors Mol Ther 2011 19 2269-76
Sheehy SH, Duncan CJ, Elias SC, et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans Mol Ther 2012a 20 2355-68
Sheehy SH, Duncan CJ, Elias SC, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors PLoS One 2012b 7 e31208
Silmon de Monerri NC, Flynn HR, Campos MG, et al. Global identification of multiple substrates for Plasmodium falciparum SUB1, an essential malarial processing protease Infect Immun 2011 79 1086-97
Sim BK, Chitnis CE, Wasniowska K, et al. Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum Science 1994 264 1941-4
Singh B, Daneshvar C Human infections and detection of Plasmodium knowlesi Clin Microbiol Rev 2013 26 165-84
Singh S, More KR, Chitnis CE Role of calcineurin and actin dynamics in regulated secretion of microneme proteins in Plasmodium falciparum merozoites during erythrocyte invasion Cell Microbiol 2014 16 50-63
Singh S, Soe S, Weisman S, et al. A conserved multi-gene family induces cross-reactive antibodies effective in defense against Plasmodium falciparum PLoS One 2009 4 e5410
Sirima SB, Cousens S, Druilhe P Protection against malaria by MSP3 candidate vaccine New Engl J Med 2011 365 1062-4
Sirima SB, Nebie I, Ouedraogo A, et al. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa Vaccine 2007 25 2723-32
Sirima SB, Tiono AB, Ouedraogo A, et al. Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children PLoS One 2009 4 e7549
Smythe JA, Coppel RL, Day KP, et al. Structural diversity in the Plasmodium falciparum merozoite surface antigen 2 P Natl Acad Sci USA 1991 88 1751-5
Soares IS, Levitus G, Souza JM, et al. Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria Infect Immun 1997 65 1606-14
Souza-Silva FA, da Silva-Nunes M, Sanchez BA, et al. Naturally acquired antibodies to Plasmodium vivax Duffy binding protein (DBP) in Brazilian Amazon Am J Trop Med Hyg 2010 82 185-93
Srinivasan P, Beatty WL, Diouf A, et al. Binding of Plasmodium merozoite proteins RON2 and AMA1 triggers commitment to invasion P Natl Acad Sci USA 2011 108 13275-80
Stafford WH, Blackman MJ, Harris A, et al. N-terminal amino acid sequence of the Plasmodium falciparum merozoite surface protein-1 polypeptides Mol Biochem Parasit 1994 66 157-60
Stafford WH, Gunder B, Harris A, et al. A 22 kDa protein associated with the Plasmodium falciparum merozoite surface protein-1 complex Mol Biochem Parasit 1996 80 159-69
Stanisic DI, Javati S, Kiniboro B, et al. Naturally acquired immune responses to P. vivax merozoite surface protein 3alpha and merozoite surface protein 9 are associated with reduced risk of P. vivax malaria in young Papua New Guinean children PLoS Neglect Trop D 2013 7 e2498
Stanisic DI, Richards JS, McCallum FJ, et al. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness Infect Immun 2009 77 1165-74
Stoute JA, Gombe J, Withers MR, et al. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya Vaccine 2007 25 176-84
Stubbs J, Olugbile S, Saidou B, et al. Strain-transcending Fc-dependent killing of Plasmodium falciparum by merozoite surface protein 2 allele-specific human antibodies Infect Immun 2011 79 1143-52
Stubbs J, Simpson KM, Triglia T, et al. Molecular mechanism for switching of P. falciparum invasion pathways into human erythrocytes Science 2005 309 1384-7
Sturchler D, Berger R, Rudin C, et al. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults Am J Trop Med Hyg 1995 53 423-31
Sutherland CJ, Tanomsing N, Nolder D, et al. Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally J Infect Dis 2010 201 1544-50
Taylor RR, Allen SJ, Greenwood BM, et al. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria Am J Trop Med Hyg 1998 58 406-13
Terheggen U, Drew DR, Hodder AN, et al. Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines BMC Med 2014 12 183
Tham WH, Healer J, Cowman AF Erythrocyte and reticulocyte binding-like proteins of Plasmodium falciparum Trends Parasitol 2012 28 23-30
Tham WH, Schmidt CQ, Hauhart RE, et al. Plasmodium falciparum uses a key functional site in complement receptor type-1 for invasion of human erythrocytes Blood 2011 118 1923-33
Tham WH, Wilson DW, Lopaticki S, et al. Complement receptor 1 is the host erythrocyte receptor for Plasmodium falciparum PfRh4 invasion ligand P Natl Acad Sci USA 2010 107 17327-32
Theisen M, Soe S, Oeuvray C, et al. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro Infect Immun 1998 66 11-17
Thera MA, Doumbo OK, Coulibaly D, et al. Safety and allele-specific immunogenicity of a malaria vaccine in malian adults: results of a phase i randomized trial PLoS Clin Trials 2006 1 e34
Thera MA, Doumbo OK, Coulibaly D, et al. Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial PLoS One 2008 3 e1465
Thera MA, Doumbo OK, Coulibaly D, et al. Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial PLoS One 2010 5 e9041
Thera MA, Doumbo OK, Coulibaly D, et al. A field trial to assess a blood-stage malaria vaccine New Engl J Med 2011 365 1004-13
Thompson J, Cooke RE, Moore S, et al. PTRAMP; a conserved Plasmodium thrombospondin-related apical merozoite protein Mol Biochem Parasit 2004 134 225-32
Thompson FM, Porter DW, Okitsu SL, et al. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial PLoS One 2008 3 e1493
Tine JA, Lanar DE, Smith DM, et al. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria Infect Immun 1996 64 3833-44
Tonkin ML, Roques M, Lamarque MH, et al. Host cell invasion by apicomplexan parasites: insights from the co-structure of AMA1 with a RON2 peptide Science 2011 333 463-7
Topolska AE, Lidgett A, Truman D, et al. Characterization of a membrane-associated rhoptry protein of Plasmodium falciparum J Biol Chem 2004a 279 4648-56
Topolska AE, Richie TL, Nhan DH, et al. Associations between responses to the rhoptry-associated membrane antigen of Plasmodium falciparum and immunity to malaria infection Infect Immun 2004b 72 3325-30
Tossavainen H, Pihlajamaa T, Huttunen TK, et al. The layered fold of the TSR domain of P. falciparum TRAP contains a heparin binding site Protein Sci 2006 15 1760-8
Tran TM, Oliveira-Ferreira J, Moreno A, et al. Comparison of IgG reactivities to Plasmodium vivax merozoite invasion antigens in a Brazilian Amazon population Am J Trop Med Hyg 2005 73 244-55
Tran TM, Ongoiba A, Coursen J, et al. Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria J Infect Dis 2014 209 789-98
Treeck M, Zacherl S, Herrmann S, et al. Functional analysis of the leading malaria vaccine candidate AMA-1 reveals an essential role for the cytoplasmic domain in the invasion process PLoS Pathog 2009 5 e1000322
Triglia T, Chen L, Lopaticki S, et al. Plasmodium falciparum merozoite invasion is inhibited by antibodies that target the PfRh2a and b binding domains PLoS Pathog 2011 7 e1002075
Trucco C, Fernandez-Reyes D, Howell S, et al. The merozoite surface protein 6 gene codes for a 36 kDa protein associated with the Plasmodium falciparum merozoite surface protein-1 complex Mol Biochem Parasit 2001 112 91-101
Tucker RP The thrombospondin type 1 repeat superfamily Int J Biochem Cell B 2004 36 969-74
Uthaipibull C, Aufiero B, Syed SE, et al. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum J Mol Biol 2001 307 1381-94
Valero MV, Amador LR, Galindo C, et al. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia [see comments] Lancet 1993 341 705-10
van Dijk MR, van Schaijk BC, Khan SM, et al. Three members of the 6-cys protein family of Plasmodium play a role in gamete fertility PLoS Pathog 2010 6 e1000853
Versiani FG, Almeida ME, Melo GC, et al. High levels of IgG3 anti ICB2-5 in Plasmodium vivax-infected individuals who did not develop symptoms Malaria J 2013 12 294
Vicentin EC, Francoso KS, Rocha MV, et al. Invasion-inhibitory antibodies elicited by immunization with Plasmodium vivax apical membrane antigen-1 expressed in Pichia pastoris yeast Infect Immun 2014 82 1296-307
Vijay Kumar S, Ranjan S, Saxena V, et al. Plasmodium falciparum: genetic diversity of C-terminal region of MSP-1 in isolates from Indian sub-continent Exp Parasitol 2005 110 384-8
Wang L, Black CG, Marshall VM, et al. Structural and antigenic properties of merozoite surface protein 4 of Plasmodium falciparum Infect Immun 1999 67 2193-200
Weiss GE, Gilson PR, Taechalertpaisarn T, et al. Revealing the sequence and resulting cellular morphology of receptor-ligand interactions during Plasmodium falciparum invasion of erythrocytes PLoS Pathog 2015 11 e1004670
Wilson DW, Fowkes FJ, Gilson PR, et al. Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans PLoS One 2011 6 e27705
Wilson DW, Goodman CD, Sleebs BE, et al. Macrolides rapidly inhibit red blood cell invasion by the human malaria parasite, Plasmodium falciparum BMC Biol 2015 13 52
Wilson DW, Langer C, Goodman CD, et al. Defining the timing of action of antimalarial drugs against Plasmodium falciparum Antimicrob Agents Ch 2013 57 1455-67
Withers MR, McKinney D, Ogutu BR, et al. Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase ib dose-escalation trial in kenyan children PLoS Clin Trials 2006 1 e32
Withers-Martinez C, Strath M, Hackett F, et al. The malaria parasite egress protease SUB1 is a calcium-dependent redox switch subtilisin Nat Commun 2014 5 3726
Withers-Martinez C, Suarez C, Fulle S, et al. Plasmodium subtilisin-like protease 1 (SUB1): insights into the active-site structure, specificity and function of a pan-malaria drug target Int J Parasitol 2012 42 597-612
Woehlbier U, Epp C, Kauth CW, et al. Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum Infect Immun 2006 74 1313-22
Woodberry T, Minigo G, Piera KA, et al. Antibodies to Plasmodium falciparum and Plasmodium vivax merozoite surface protein 5 in Indonesia: species-specific and cross-reactive responses J Infect Dis 2008 198 134-42
World Health Organization World Malaria Report Geneva World Health Organization 2014
Wright KE, Hjerrild KA, Bartlett J, et al. Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies Nature 2014 515 427-30
Wu T, Black CG, Wang L, et al. Lack of sequence diversity in the gene encoding merozoite surface protein 5 of Plasmodium falciparum Mol Biochem Parasit 1999 103 243-50
Yang X, Adda CG, MacRaild CA, et al. Identification of key residues involved in fibril formation by the conserved N-terminal region of Plasmodium falciparum merozoite surface protein 2 (MSP2) Biochimie 2010 92 1287-95
Yap A, Azevedo MF, Gilson PR, et al. Conditional expression of apical membrane antigen 1 in Plasmodium falciparum shows it is required for erythrocyte invasion by merozoites Cell Microbiol 2014 16 642-56
Yeoh S, O'Donnell RA, Koussis K, et al. Subcellular discharge of a serine protease mediates release of invasive malaria parasites from host erythrocytes Cell 2007 131 1072-83
Yeom JS, Kim ES, Lim KJ, et al. Naturally acquired IgM antibody response to the C-terminal region of the merozoite surface protein 1 of Plasmodium vivax in Korea: use for serodiagnosis of vivax malaria J Parasitol 2008 94 1410-4
Yildiz Zeyrek F, Palacpac N, Yuksel F, et al. Serologic markers in relation to parasite exposure history help to estimate transmission dynamics of Plasmodium vivax PLoS One 2011 6 e28126
Zenonos ZA, Dummler SK, Muller-Sienerth N, et al. Basigin is a druggable target for host-oriented antimalarial interventions J Exp Med 2015 212 1145-51
Zhang X, Perugini MA, Yao S, et al. Solution conformation, backbone dynamics and lipid interactions of the intrinsically unstructured malaria surface protein MSP2 J Mol Biol 2008 379 105-21
|
Language: | English.
|
Document Type: | Review Article.
|
Journal Subset: | Life & Biomedical Sciences.
|
ISSN: | 0168-6445
|
DOI Number: | https://dx.doi.org/10.1093/femsr...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|